Related Experiment Video

Updated: Aug 19, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

MicroRNA-143-3p Inhibits Wilms' Tumor Cell Growth By Targeting the Ras/Raf/MEK/ERK Pathway

Lianhai Zhang, Wei Shao

    Alternative Therapies in Health and Medicine
    |December 1, 2022
    PubMed
    Abstract

    Insights

    MicroRNA-143-3p (miR-143-3p) is downregulated in Wilms' tumor (WT) and inhibits cancer cell proliferation. This microRNA may serve as a prognostic biomarker and therapeutic target for WT.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Genetics

    Background:

    • MicroRNA-143-3p (miR-143-3p) is a known tumor suppressor in various cancers.
    • The specific roles and molecular mechanisms of miR-143-3p in Wilms' tumor (WT) progression require further investigation.

    Purpose of the Study:

    • To determine the expression levels and biological functions of miR-143-3p in Wilms' tumor (WT).
    • To elucidate the molecular mechanisms underlying miR-143-3p's role in WT progression.

    Main Methods:

    • Quantitative-reverse transcription polymerase chain reaction (qRT-PCR) to measure miR-143-3p expression in WT tissues.
    • Western blotting to assess protein expression in related signaling pathways.
    • Cell line experiments involving miR-143-3p overexpression and k-Ras manipulation.

    Main Results:

    • miR-143-3p expression was significantly downregulated in WT tissues and correlated with advanced tumor stage and lymph node metastasis.
    • Overexpression of miR-143-3p inhibited WT cell proliferation via G0/G1 cell cycle arrest and apoptosis induction.
    • k-Ras was identified as a direct target of miR-143-3p; its modulation affected WT cell proliferation, and it reversed miR-143-3p's inhibitory effects.

    Conclusions:

    • miR-143-3p acts as a tumor suppressor in Wilms' tumor.
    • miR-143-3p demonstrates potential as a novel prognostic biomarker and therapeutic target for WT.

    More Related Videos

    An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

    An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

    Published on: May 21, 2019

    8.4K
    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

    Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

    Published on: October 5, 2020

    3.1K

    Related Concept Videos

    MicroRNAs01:22

    MicroRNAs

    MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
    21.5K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.9K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    3.8K
    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
    4.6K
    MAPK Signaling Cascades01:07

    MAPK Signaling Cascades

    Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
    5.9K
    Experimental RNAi02:15

    Experimental RNAi

    RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
    6.2K